Bristol-Myers Squibb to report hepatitis C drug data at 2015 Liver Meeting

Bristol-Myers Squibb has announced that it will be presenting 17 abstracts on hepatitis C therapies at the 2015 Liver Meeting in San Francisco.

The company will attend the annual meeting of the American Association for the Study of Liver Diseases from November 13th to 17th, during which it will detail the findings of multiple studies of difficult-to-treat chronic hepatitis C cases.

Highlights will include real-world data on the treatment of chronic hepatitis C populations, including genotype 3 patients, post-liver transplant patients, patients with advanced liver disease and those coinfected with HIV.

Additionally, late-breaking data from the ALLY-3+ clinical trial will be presented, providing information on the performance of Daklinza plus sofosbuvir and ribavirin in genotype 3 hepatitis C patients with cirrhosis.

Dr Douglas Manion, head of specialty development at Bristol-Myers Squibb, said: "The data to be presented at this year's AASLD conference reinforces Bristol-Myers Squibb’s ongoing commitment to investigating Daklinza-based treatments that could address the still-challenging needs of many patients living with chronic viral hepatitis C."

This comes after the National Institute for Health and Care Excellence recommended Daklinza for NHS use earlier this month.